Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 6
1966 6
1967 1
1968 2
1969 2
1970 3
1971 6
1972 5
1973 6
1974 9
1975 8
1976 11
1977 7
1978 7
1979 13
1980 15
1981 19
1982 15
1983 16
1984 22
1985 21
1986 25
1987 15
1988 19
1989 10
1990 23
1991 16
1992 15
1993 11
1994 10
1995 10
1996 10
1997 8
1998 8
1999 2
2000 8
2001 7
2002 6
2003 9
2004 6
2005 6
2006 7
2007 4
2008 9
2009 9
2010 3
2011 8
2012 14
2013 6
2014 11
2015 4
2016 13
2017 14
2018 11
2019 6
2020 4
2021 8
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

550 results
Results by year
Filters applied: . Clear all
Page 1
Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.
Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, Tu W. Agarwal R, et al. N Engl J Med. 2021 Dec 30;385(27):2507-2519. doi: 10.1056/NEJMoa2110730. Epub 2021 Nov 5. N Engl J Med. 2021. PMID: 34739197 Free PMC article. Clinical Trial.
The percent change in the urinary albumin-to-creatinine ratio from baseline to 12 weeks was lower in the chlorthalidone group than in the placebo group by 50 percentage points (95% CI, 37 to 60). Hypokalemia, reversible increases in serum creatinine level, hyperglycemia, d …
The percent change in the urinary albumin-to-creatinine ratio from baseline to 12 weeks was lower in the chlorthalidone group than in …
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981. JAMA. 2002. PMID: 12479763 Clinical Trial.
INTERVENTIONS: Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); amlodipine, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 years. ...For amlodipine vs chlorthal
INTERVENTIONS: Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); amlodipine, 2.5 to 10 mg/ …
Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial.
Agarwal R, Cramer AE, Balmes-Fenwick M, Sinha AD, Ouyang F, Tu W. Agarwal R, et al. Am J Nephrol. 2020;51(7):542-552. doi: 10.1159/000508700. Epub 2020 Jul 14. Am J Nephrol. 2020. PMID: 32663820 Free PMC article. Clinical Trial.
BACKGROUND: Hypertension often accompanies chronic kidney disease (CKD), and diuretics are widely prescribed to reduce blood pressure (BP). Chlorthalidone (CTD) is a thiazide-like diuretic and an effective antihypertensive drug, yet little data exist to support its use in …
BACKGROUND: Hypertension often accompanies chronic kidney disease (CKD), and diuretics are widely prescribed to reduce blood pressure (BP). …
Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial.
Fuchs FD, Scala LCN, Vilela-Martin JF, Whelton PK, Poli-de-Figueiredo CE, Pereira E Silva R, Gus M, Bortolotto LA, Consolim-Colombo FM, Schlatter RP, Cesarino JE, Castro I, Figueiredo Neto JA, Chaves H, Steffens AA, Alves JG, Brandão AA, de Sousa MR, Jardim PC, Moreira LB, Franco RS, Gomes MM, Afiune Neto A, Fuchs FC, Sobral Filho DC, Nóbrega AC, Nobre F, Berwanger O, Fuchs SC. Fuchs FD, et al. Acta Diabetol. 2021 Feb;58(2):215-220. doi: 10.1007/s00592-020-01611-8. Epub 2020 Oct 13. Acta Diabetol. 2021. PMID: 33047257 Clinical Trial.
AIMS: To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of JNC 7 Stage I hypertension in patients with type 2 diabetes mellitus. ...CONCLUSIONS: Treatment of hypertension based on a …
AIMS: To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initi …
Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study.
Agarwal R, Sinha AD, Pappas MK, Ammous F. Agarwal R, et al. Am J Nephrol. 2014;39(2):171-82. doi: 10.1159/000358603. Epub 2014 Feb 11. Am J Nephrol. 2014. PMID: 24526255 Free article. Clinical Trial.
Albuminuria was significantly reduced by 40-45%. Adverse events were seen following chlorthalidone therapy in 7 subjects who experienced 18 events as follows: hypokalemia (n = 4), hyperuricemia (4), hyponatremia (3), transient creatinine changes (3), dizziness (2), hypergl …
Albuminuria was significantly reduced by 40-45%. Adverse events were seen following chlorthalidone therapy in 7 subjects who experien …
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
[No authors listed] [No authors listed] JAMA. 1991 Jun 26;265(24):3255-64. JAMA. 1991. PMID: 2046107 Clinical Trial.
INTERVENTIONS: --Participants were stratified by clinical center and by antihypertensive medication status at initial contact. For step 1 of the trial, dose 1 was chlorthalidone, 12.5 mg/d, or matching placebo; dose 2 was 25 mg/d. For step 2, dose 1 was atenolol, 25 mg/d, …
INTERVENTIONS: --Participants were stratified by clinical center and by antihypertensive medication status at initial contact. For step 1 of …
Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial.
Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, Amarasekara S, Amarasena N, Billot L, de Silva AP, Fernando M, Guggilla R, Jan S, Jayawardena J, Maulik PK, Mendis S, Mendis S, Munasinghe J, Naik N, Prabhakaran D, Ranasinghe G, Thom S, Tisserra N, Senaratne V, Wijekoon S, Wijeyasingam S, Rodgers A, Patel A; TRIUMPH Study Group. Webster R, et al. JAMA. 2018 Aug 14;320(6):566-579. doi: 10.1001/jama.2018.10359. JAMA. 2018. PMID: 30120478 Free PMC article. Clinical Trial.
INTERVENTIONS: A once-daily fixed-dose triple combination pill (20 mg of telmisartan, 2.5 mg of amlodipine, and 12.5 mg of chlorthalidone) therapy (n = 349) or usual care (n = 351). MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion achieving target systoli …
INTERVENTIONS: A once-daily fixed-dose triple combination pill (20 mg of telmisartan, 2.5 mg of amlodipine, and 12.5 mg of chlorthalidone
Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.
Edwards NC, Price AM, Mehta S, Hiemstra TF, Kaur A, Greasley PJ, Webb DJ, Dhaun N, MacIntyre IM, Farrah T, Melville V, Herrey AS, Slinn G, Wale R, Ives N, Wheeler DC, Wilkinson I, Steeds RP, Ferro CJ, Townend JN. Edwards NC, et al. Clin J Am Soc Nephrol. 2021 Oct;16(10):1491-1501. doi: 10.2215/CJN.01930221. Epub 2021 Aug 30. Clin J Am Soc Nephrol. 2021. PMID: 34462286 Free PMC article. Clinical Trial.
A decline in eGFR >30% occurred in eight participants treated with chlorthalidone compared with two participants with spironolactone (adjusted relative risk was 0.2, 95% confidence interval, 0.05 to 1.1, P=0.07). CONCLUSIONS: Spironolactone was not superior to chlort
A decline in eGFR >30% occurred in eight participants treated with chlorthalidone compared with two participants with spironolacto …
A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone.
Weber MA, Sever P, Juhasz A, Roberts A, Cao C. Weber MA, et al. J Renin Angiotensin Aldosterone Syst. 2018 Jul-Sep;19(3):1470320318795000. doi: 10.1177/1470320318795000. J Renin Angiotensin Aldosterone Syst. 2018. PMID: 30175930 Free PMC article. Clinical Trial.
INTRODUCTION: We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertension. METHODS: Azilsartan medoxomil 40 or 80 mg plus chlorthalidone were compared with placebo plus chlorthalidone once daily in a rando …
INTRODUCTION: We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertension. METH …
Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR; ALLHAT Collaborative Research Group. Bangalore S, et al. Am J Med. 2017 Apr;130(4):439-448.e9. doi: 10.1016/j.amjmed.2016.10.002. Epub 2016 Oct 27. Am J Med. 2017. PMID: 27984005 Free PMC article. Clinical Trial.
During mean follow-up of 2.9 years, primary outcome incidence was similar for those assigned to chlorthalidone compared with amlodipine or lisinopril (amlodipine- vs chlorthalidone-adjusted hazard ratio [HR] 0.86; 95% confidence interval [CI], 0.53-1.39; P = .53; li …
During mean follow-up of 2.9 years, primary outcome incidence was similar for those assigned to chlorthalidone compared with amlodipi …
550 results